Emerging and potential therapies for osteoporosis
- 1 March 2005
- journal article
- review article
- Published by Informa UK Limited in Expert Opinion on Investigational Drugs
- Vol. 14 (3), 265-278
- https://doi.org/10.1517/13543784.14.3.265
Abstract
Osteoporotic fractures are an important public health problem, contributing substantially to morbidity and mortality in an ageing world population and consuming considerable health resources. Currently available pharmaco-l-ogical therapies for prevention of fragility fractures are limited in scope, efficacy and acceptability to patients. Considerable efforts are being made to develop new, more effective treatments for osteoporosis and to refine/optimise existing therapies. These novel treatments include an expanding array of drugs that primarily inhibit osteoclastic bone resorption; oestrogenic compounds, bisphosphonates, inhibitors of receptor activator of nuclear factor-κB ligand signalling, cathepsin K inhibitors, c-src kinase inhibitors, integrin inhibitors and chloride channel inhibitors. The advent of intermittent para-thyroid hormone (PTH) therapy has provided proof-of-principle that osteo-blast-targeted (anabolic) agents can effectively prevent osteoporotic fractures, and is likely to be followed ...Keywords
This publication has 114 references indexed in Scilit:
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human boneJournal of Bone and Mineral Metabolism, 2004
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- MEPE has the properties of an osteoblastic phosphatonin and minhibinBone, 2004
- Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without OsteoporosisJournal of Bone and Mineral Research, 2004
- Chloride Channel ClCN7 Mutations Are Responsible for Severe Recessive, Dominant, and Intermediate OsteopetrosisJournal of Bone and Mineral Research, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 2002
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- Lasofoxifene (CP-336,156) Protects Against the Age-Related Changes in Bone Mass, Bone Strength, and Total Serum Cholesterol in Intact Aged Male RatsJournal of Bone and Mineral Research, 2001